Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Current recommendation for asthma treatment].

Piotr Kuna1

  • 1Klinika Pneumonologii i Alergologii Instytutu Medycyny Wewnetrznej Uniwersytetu Medycznego w Lodzi. pkuna@bg.p.lodz.pl

Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego
|November 5, 2004
PubMed
Summary

Asthma management involves patient education, allergen avoidance, and anti-inflammatory treatments. New fast and long-acting beta2-agonists, combined with inhaled steroids, offer effective symptom control for chronic asthma.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild-to-moderate asthma.

British journal of clinical pharmacology·2026
Same author

Severe asthma and remission prospects in Europe (SHARP): insights from a multicentre observational study based on the European Severe Asthma Registry.

The Lancet. Respiratory medicine·2026
Same author

Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.

Nature medicine·2026
Same author

Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.

Nature medicine·2026
Same author

Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines-2024-2025 Revision: Part II-Guidelines on Oral and Ocular Treatments.

Allergy·2026
Same author

Multimorbidity phenotypes and associated characteristics in severe asthma: an observational study of European severe asthma registries.

The Lancet regional health. Europe·2026

Area of Science:

  • Pulmonology
  • Allergy and Immunology
  • Pharmacology

Context:

  • Asthma is a chronic respiratory disease defined by airway inflammation, reversible obstruction, and hyperresponsiveness.
  • Key symptoms include cough, wheezing, and dyspnea, necessitating diagnosis via beta2-agonist reversibility testing.

Purpose:

  • To outline current diagnostic and management strategies for asthma.
  • To highlight the role of new pharmacological agents and combination therapies in achieving disease control.

Summary:

  • Diagnosis relies on reversible bronchial obturation and hyperresponsiveness, confirmed by beta2-agonist testing.
  • Management integrates patient education, allergen avoidance, and anti-inflammatory therapies.
  • Combination treatments with long-acting beta2-agonists and topical glucocorticosteroids are recommended for moderate to severe chronic asthma.

Related Experiment Videos

Impact:

  • Newer medications, including fast and long-acting beta2-agonists, have improved asthma symptom control.
  • Combination therapies and alternative options like antileukotrienes and theophylline offer effective management for difficult-to-control cases.
  • Integrated care, addressing comorbidities like rhinitis and considering immunotherapy for atopic asthma, contributes to comprehensive disease management and improved patient outcomes.